Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18669712 | ENDONUCLEASE SYSTEMS | May 2024 | May 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18597673 | RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES | March 2024 | December 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18472824 | ENGINEERED RETRONS AND METHODS OF USE | September 2023 | March 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18457276 | ENGINEERED ADENOSINE DEAMINASES AND BASE EDITORS THEREOF | August 2023 | August 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18447536 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | February 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18447681 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | June 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18447515 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | August 2023 | February 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18356013 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | July 2023 | February 2024 | Allow | 7 | 0 | 1 | Yes | No |
| 18127936 | IMMUNOENGINEERED PLURIPOTENT CELLS | March 2023 | September 2024 | Abandon | 18 | 0 | 0 | No | No |
| 18190063 | CRISPR SYSTEMS WITH ENGINEERED DUAL GUIDE NUCLEIC ACIDS | March 2023 | December 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 18120007 | USE NOVEL LIGHT SENSITIVE CHANNEL PROTEIN VR 1.0 IN PREPARATION OF RETINAL PHOTORECEPTOR CELL DEGENERATIVE DISEASE DRUG | March 2023 | January 2024 | Allow | 10 | 1 | 0 | No | No |
| 18161560 | ENGINEERED MEGANUCLEASES THAT TARGET HUMAN MITOCHONDRIAL GENOMES | January 2023 | August 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 18101867 | ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS, ENZYMES AND GUIDE SCAFFOLDS OF CAS9 ORTHOLOGS AND VARIANTS FOR SEQUENCE MANIPULATION | January 2023 | September 2024 | Allow | 20 | 1 | 0 | No | No |
| 18087673 | ENGINEERED RETRONS AND METHODS OF USE | December 2022 | September 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18049582 | ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | October 2022 | June 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17931535 | Guide RNAs with Chemical Modification for Prime Editing | September 2022 | September 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 17781877 | Therapeutic Editing | June 2022 | August 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17825665 | CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOF | May 2022 | June 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17751195 | Adeno-Associated Virus Vector Delivery of a Fragment of Micro-Dystrophin to Treat Muscular Dystrophy | May 2022 | October 2023 | Allow | 17 | 3 | 0 | Yes | No |
| 17748889 | Immunocompetent Cell and Expression Vector Expressing Regulatory Factors of Immune Function | May 2022 | November 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17710464 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS TARGETING TRIM7 | March 2022 | May 2024 | Allow | 26 | 1 | 1 | No | No |
| 17654300 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING F8 GENE FUNCTION AND METHODS OF USE THEREOF | March 2022 | July 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17580228 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND MICRORNA-29 AND THE TREATMENT OF MUSCULAR DYSTROPHY | January 2022 | October 2023 | Allow | 21 | 2 | 0 | Yes | No |
| 17525283 | METHOD FOR CONSTRUCTING TREHALOSE MULTI-ENZYME COMPLEX IN VITRO MEDIATED BY ARTIFICIAL SCAFFOLD PROTEIN | November 2021 | May 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17523821 | ELECTROPORATION MODULES AND INSTRUMENTATION | November 2021 | January 2023 | Allow | 15 | 1 | 0 | No | No |
| 17506419 | METHODS AND COMPOSITIONS FOR DIRECTED GENOME EDITING | October 2021 | February 2025 | Abandon | 40 | 2 | 1 | No | No |
| 17494457 | Gene Editing-Based Method of Attenuating the Beta-Amyloid Pathway | October 2021 | February 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17490416 | HUMAN PAH EXPRESSION CASSETTE FOR TREATMENT OF PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY | September 2021 | July 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17486735 | Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent | September 2021 | April 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17468086 | SYSTEMIC DELIVERY OF ADENO-ASSOCIATED VIRUS VECTOR EXPRESSING GAMMA-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY | September 2021 | January 2024 | Allow | 28 | 2 | 1 | No | No |
| 17461716 | CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOF | August 2021 | January 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17368216 | BUDDING YEAST WITH HUMAN CHROMATIN | July 2021 | June 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17365846 | SYNTHETIC DNA VECTORS AND METHODS OF USE | July 2021 | February 2023 | Allow | 20 | 2 | 1 | Yes | No |
| 17244574 | GENE THERAPY VECTOR FOR TREATING RETINITIS PIGMENTOSA DISEASE | April 2021 | August 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17239540 | COMPOSITIONS, METHODS, MODULES AND INSTRUMENTS FOR AUTOMATED NUCLEIC ACID-GUIDED NUCLEASE EDITING IN MAMMALIAN CELLS USING MICROCARRIERS | April 2021 | October 2022 | Allow | 18 | 3 | 1 | Yes | No |
| 17236556 | GENETIC DATA COMPRESSION AND METHODS OF USE | April 2021 | March 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17230484 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS | April 2021 | April 2023 | Allow | 24 | 1 | 0 | No | No |
| 17279271 | METHOD FOR PROMOTING N-ACETYLGLUCOSAMINE SYNTHESIS BY USING GLCN6P RESPONSIVE ELEMENT | March 2021 | December 2024 | Allow | 45 | 1 | 0 | No | No |
| 17206522 | METHODS AND COMPOSITIONS FOR DIRECTED GENOME EDITING | March 2021 | October 2021 | Allow | 7 | 2 | 1 | Yes | No |
| 17180741 | GENETIC TOOLBOX FOR METABOLIC ENGINEERING OF NON-CONVENTIONAL YEAST | February 2021 | June 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17178737 | COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES | February 2021 | January 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17173137 | INCREASED NUCLEIC-ACID GUIDED CELL EDITING IN YEAST | February 2021 | October 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17158488 | ELECTROPORATION MODULES AND INSTRUMENTATION | January 2021 | November 2021 | Allow | 9 | 2 | 1 | Yes | No |
| 17132694 | IDENTIFICATION OF SPATIAL BIOMARKERS OF HEART DISORDERS AND METHODS OF USING THE SAME | December 2020 | September 2024 | Abandon | 45 | 2 | 1 | Yes | No |
| 17039575 | Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy Regeneration | September 2020 | November 2024 | Allow | 50 | 3 | 1 | No | No |
| 17032657 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | September 2020 | September 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16966682 | DRUG FOR CHRONIC INFLAMMATORY DISEASE AND METHOD FOR EVALUATING SUSCEPTIBILITY TO CHRONIC INFLAMMATORY DISEASE | July 2020 | March 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16934970 | SYNTHETIC GENETIC ELEMENTS FOR BIOMANUFACTURE | July 2020 | January 2024 | Allow | 42 | 1 | 1 | No | No |
| 16933780 | CAPSID-MODIFIED RAAV VECTORS AND METHODS OF USE | July 2020 | April 2025 | Abandon | 57 | 2 | 0 | No | No |
| 16920051 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | July 2020 | January 2024 | Abandon | 43 | 1 | 0 | No | No |
| 16769522 | ENGINEERED UBIQUITOUS CHROMATIN OPENING ELEMENTS AND USES THEREOF | June 2020 | October 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16881871 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | May 2020 | October 2023 | Allow | 41 | 2 | 0 | Yes | No |
| 16871736 | EXPRESSION CONSTRUCTS, HOST CELLS, AND METHODS FOR PRODUCING INSULIN | May 2020 | April 2025 | Abandon | 59 | 3 | 1 | No | No |
| 16756756 | METHODS AND COMPOSITIONS FOR TREATING AND PROTECTING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | April 2020 | March 2024 | Allow | 47 | 1 | 2 | Yes | No |
| 16842679 | AAV CAPSID DESIGNS | April 2020 | January 2025 | Abandon | 57 | 5 | 0 | No | No |
| 16651779 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEART FAILURE | March 2020 | September 2024 | Allow | 54 | 2 | 1 | Yes | No |
| 16623052 | Demethylation of Reticuline and Derivatives Thereof with Fungal Cytochrome P450 | December 2019 | May 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16685565 | PURIFICATION AND IDENTIFICATION OF A PROTEIN COMPLEX CONTAINING B-CELL LYMPHOMA PROTEIN (BCL10) | November 2019 | November 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16494645 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF A FRAGMENT OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | September 2019 | January 2022 | Allow | 28 | 1 | 0 | Yes | No |
| 16492878 | RIBOSWITCH MODULATED GENE THERAPY FOR RETINAL DISEASES | September 2019 | January 2024 | Allow | 52 | 1 | 1 | Yes | No |
| 16563573 | UNIVERSAL DONOR CELLS | September 2019 | March 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16512482 | Expression Constructs and Methods for Expressing Polypeptides in Eukaryotic Cells | July 2019 | December 2024 | Abandon | 60 | 1 | 1 | No | No |
| 16457528 | COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES | June 2019 | July 2023 | Allow | 49 | 2 | 1 | Yes | No |
| 16453260 | METHOD TO BUILD FUNGAL PRODUCTION STRAINS USING AUTOMATED STEPS FOR GENETIC MANIPULATION AND STRAIN PURIFICATION | June 2019 | October 2022 | Abandon | 40 | 4 | 1 | Yes | Yes |
| 16472793 | ADENO ASSOCIATED VIRAL VECTORS | June 2019 | March 2025 | Allow | 60 | 1 | 1 | No | No |
| 16341504 | AAV CAPSID DESIGNS | April 2019 | September 2022 | Allow | 42 | 2 | 1 | Yes | No |
| 16279688 | ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RESTORING F8 GENE FUNCTION AND METHODS OF USE THEREOF | February 2019 | December 2021 | Allow | 34 | 1 | 1 | Yes | No |
| 16270198 | CONSTRUCTS AND METHODS FOR SIGNAL AMPLIFICATION | February 2019 | August 2021 | Abandon | 31 | 2 | 0 | No | No |
| 16322518 | Method for Producing Recombinant Protein | February 2019 | February 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16320280 | BCL11A HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | January 2019 | June 2022 | Abandon | 40 | 1 | 0 | No | No |
| 16252934 | NOVEL SACCHAROMYCES CEREVISIAE EXPRESSION SYSTEM AND CONSTRUCTION METHOD THEREOF | January 2019 | February 2022 | Abandon | 37 | 2 | 1 | No | No |
| 16251970 | Gene Editing-based Method of Attenuating the Beta-Amyloid Pathway | January 2019 | July 2021 | Allow | 29 | 2 | 0 | Yes | No |
| 16309074 | Cell-Free Expression System Having Novel Inorganic Polyphosphate-Based Energy Regeneration | December 2018 | July 2021 | Allow | 31 | 3 | 0 | Yes | No |
| 16308335 | NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO | December 2018 | February 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 16300223 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | November 2018 | August 2024 | Abandon | 60 | 2 | 1 | No | No |
| 16300196 | A CELL-BASED ARRAY PLATFORM | November 2018 | March 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16179523 | SOLID PHASE NEGATIVE ENRICHMENT | November 2018 | May 2023 | Abandon | 54 | 3 | 0 | No | No |
| 16177784 | BODILY FLUID ENRICHMENT | November 2018 | May 2023 | Abandon | 54 | 3 | 0 | No | No |
| 16159116 | TUMOR DETECTION AND MONITORING | October 2018 | March 2023 | Abandon | 53 | 3 | 0 | No | No |
| 16093027 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF B-SARCOGLYCAN AND MICRORNA-29 AND THE TREATMENT OF MUSCULAR DYSTROPHY | October 2018 | August 2021 | Allow | 34 | 1 | 0 | Yes | No |
| 16150962 | SEQUENCE SPECIFIC METHYLATION ENRICHMENT AND DETECTION | October 2018 | September 2022 | Abandon | 47 | 1 | 0 | No | No |
| 16088159 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | September 2018 | November 2022 | Allow | 50 | 2 | 1 | Yes | No |
| 16084503 | IMMUNOCOMPETENT CELL AND EXPRESSION VECTOR EXPRESSING REGULATORY FACTORS OF IMMUNE FUNCTION | September 2018 | January 2022 | Allow | 40 | 1 | 1 | Yes | No |
| 16084011 | Improved CRISPR-Cpf1 Genome Editing Tool | September 2018 | September 2021 | Abandon | 36 | 0 | 1 | No | No |
| 16081989 | Methods for Making Polypeptides Including D-Amino Acids | September 2018 | February 2023 | Allow | 53 | 4 | 0 | No | No |
| 16075568 | STRUCTURE-GUIDED CHEMICAL MODIFICATION OF GUIDE RNA AND ITS APPLICATIONS | August 2018 | August 2023 | Allow | 60 | 2 | 1 | No | No |
| 16049212 | ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | July 2018 | November 2022 | Abandon | 52 | 2 | 0 | No | Yes |
| 16073947 | Compositions and Methods for Recombinant CXADR Expression | July 2018 | October 2021 | Abandon | 39 | 1 | 1 | No | No |
| 16073702 | Process for extracellular secretion of Brazzein | July 2018 | November 2022 | Allow | 52 | 4 | 1 | Yes | No |
| 16042417 | BUDDING YEAST WITH HUMAN CHROMATIN | July 2018 | March 2021 | Allow | 32 | 2 | 1 | Yes | No |
| 16018926 | BODILY FLUID TARGET ENRICHMENT | June 2018 | March 2023 | Abandon | 57 | 3 | 1 | No | No |
| 16016007 | SIGNALING CENTERS OF ERYTHROID DIFFERENTIATION | June 2018 | December 2024 | Abandon | 60 | 5 | 1 | Yes | No |
| 16009147 | CYTOPLASMIC EXPRESSION SYSTEM | June 2018 | July 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 16062036 | GROUP B ADENOVIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT | June 2018 | April 2023 | Allow | 58 | 2 | 1 | Yes | No |
| 16007531 | TUMOR MUTATION BURDEN BY QUANTIFICATION OF MUTATIONS IN NUCLEIC ACID | June 2018 | June 2022 | Abandon | 48 | 3 | 1 | No | No |
| 16061521 | METHODS AND COMPOSITIONS FOR POLYMERASE II (POL-II) BASED GUIDE RNA EXPRESSION | June 2018 | November 2023 | Abandon | 60 | 5 | 1 | No | No |
| 15867500 | MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS | January 2018 | February 2023 | Allow | 60 | 5 | 3 | Yes | No |
| 15838720 | ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS, ENZYMES AND GUIDE SCAFFOLDS OF CAS9 ORTHOLOGS AND VARIANTS FOR SEQUENCE MANIPULATION | December 2017 | September 2022 | Allow | 58 | 2 | 1 | Yes | No |
| 15566150 | DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE | October 2017 | March 2025 | Abandon | 60 | 6 | 1 | No | Yes |
| 15548535 | NOVEL METHODS FOR EARLY IDENTIFICATION OF BONE HEALING ABILITY IN INJURED PATIENTS | August 2017 | January 2022 | Allow | 54 | 2 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HASAN, KHALEDA B.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HASAN, KHALEDA B works in Art Unit 1636 and has examined 103 patent applications in our dataset. With an allowance rate of 63.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner HASAN, KHALEDA B's allowance rate of 63.1% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HASAN, KHALEDA B receive 2.03 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HASAN, KHALEDA B is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +60.4% benefit to allowance rate for applications examined by HASAN, KHALEDA B. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.